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Age-related macular degeneration (AMD) is the leading cause of blindness among the elderly. While excellent treatment has
emerged for neovascular disease, treatment for early AMD is lacking due to an incomplete understanding of the early molecular
events. A prominent age-related change is the accumulation of neutral lipid in normal Bruch’s membrane (BrM) throughout
adulthood and also disease-related BrM accumulations called basal deposits and drusen. AMD lesion formation has thus been
conceptualized as sharing mechanisms with atherosclerotic plaque formation, where low-density lipoprotein (LDL) retention
within the arterial wall initiates a cascade of pathologic events. However, we do not yet understand how lipoproteins contribute to
AMD. This paper explores how systemic and local production of lipoproteins might contribute to the pathogenesis of AMD.
1.Introduction
Age-related macular degeneration (AMD) is the leading
cause of blindness among the elderly in the United States,
representing 54% of legal blindness [1]. Currently, 1.75
million people are aﬀected by advanced AMD, and due to
the aging population, 3 million people will be aﬀected by
2020[2].Atpresent,7millionpeopleareatriskofdeveloping
advanced AMD, and 1 in 3 persons ≥70 years old with early
AMD will develop advanced disease over 10 years [1, 3]. The
devastating impact to both the individual and general public
is staggering. In Canada and Australia, the ﬁnancial impact
is estimated to be $2.6 billion on the gross domestic product
[4, 5]. The continued trend for increased life expectancy
predicts a doubling in the number of people with AMD
with costs reaching $59 billion over the next 20 years [5].
Improving treatments that reverse, prevent, or even delay
the onset of AMD would have signiﬁcant beneﬁt to both the
individual and society.
A growing body of the literature indicates the involve-
ment of lipids and lipoproteins in the formation of extracel-
lular lesions in aging Bruch’s membrane, basal deposits and
drusen, and two hallmark AMD lesions. In this paper, we
will explore the various aspects for how lipoprotein particles
might contribute to the pathogenesis of AMD.
2 .A n a t o m ya n dH is t o l ogyo ft h eM a c ul a
The retina arises from the optic vesicle and consists of a
retinal pigment epithelial (RPE) layer, which is derived from
the optic cup, and a complex sensory layer, which is derived
from the inner layer of neuroectodermal cells of the optic
cup [6]. The sensory retina is transparent, and adjacent
to the RPE, is composed of nine layers: the rod and cone
photoreceptors, the external limiting membrane, the outer
nuclear layer, the outer plexiform layer, the inner nuclear
layer which contains the nuclei of horizontal cells, bipolar
cells, amacrine cells, and Muller cells, the inner plexiform
layer, the ganglion cell layer, the nerve ﬁber layer, and the
internal limiting membrane, which is next to the vitreous gel
(Figure 1(b)). While the peripheral retina and much of the
macula, or the central retina, is dominated by rods in a 20:1
and 9:1 ratio, respectively, the central-most aspect of the
macula, called the foveola, is comprised exclusively of cones
[6–8]. This enriched area of cones and their close packing
accounts for the high visual acuity.
Clinically, the macula is deﬁned as the central retina
that is located within the vascular arcades (Figure 1(a)).
Histologically, it is the region that contains more than 1
layer of ganglion cell nuclei [9]. The term macula lutea is
derived from the yellow color of the central retina which is2 Journal of Lipids
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Figure 1: (a) Fundus photo of the right eye. The macula is located between vascular arcades with the fovea at the center approximately 3mm
temporal to the optic nerve (ON). (b) Histopathological section of the neurosensory retina from the inner (vitreous) to outer layers: nerve
ﬁber layer (NFL), ganglion cell layer (GCL), inner plexiform layer, inner nuclear layer (INL), outer plexiform layer (OPL), outer nuclear
layer (ONL), outer segments of the photoreceptors (POS), underlying retinal pigment epithelium (RPE), Bruch’s membrane (BM∗), and
choriocapillaris and choroid (Hematoxylin-eosin).
due to carotenoid pigments within the Henle ﬁber layer. Two
of the major yellow pigments that have been identiﬁed are
zeaxanthin and lutein. The former is concentrated in cone
dense areas while lutein is concentrated in rod dense areas of
retina. The fovea is a concave central depression 1.5mm in
diameter and is seen on clinical examination as an elliptical
lightreﬂexthatarisesfromtheslopeofthethickenedinternal
limiting of the retina. The foveola is a central 0.35mm
diameter depression within the fovea. Usually, only cone
photoreceptors and Muller cells are present in this area [6].
The inner retina derives its nutrition from the retinal
vascular system while the outer layers, including the outer
portion of the inner nuclear layer, derive their nutrition from
the choriocapillaris. The central 250 to 600 μm of the macula
or foveal avascular zone is free of retinal blood vessels and
derives its nutrition from the choroid [10, 11].
The neurosensory retina is supported by the retinal
pigmented epithelium (RPE), the polarized epithelial mono-
layer. Like the photoreceptors and outer retinal layers, the
RPE relies on the choroid for its nutrition [12]. The 200–
300mm thick choroid has the highest blood ﬂow per
unit tissue perfused in the body, with 7-fold greater ﬂow
in the macula relative to the periphery [13]. The RPE
plays an important role in vitamin A metabolism, outer
blood-retina barrier integrity, daily phagocytosis of the
photoreceptor outer segments, absorption of light, heat
exchange, formation of the basal lamina, production of the
mucopolysaccharidematrixsurroundingtheoutersegments,
secretion of factors that maintain the choriocapillaris, the
polarized secretion of cytokines, and active transport of
materials in and out of the RPE. In the adult eye, the RPE
is mitotically inactive [14].
The thin Bruch’s membrane (BrM) is a pentalami-
nar matrix located between RPE and choroid. BrM is
a semipermeable ﬁltration barrier through which major
metabolic exchange takes place. Ultrastructurally, it has 5
layers: the RPE basement membrane, the inner collagenous
zone, the elastic zone, the outer collagenous zone, and the
choriocapillaris basement membrane [15]. The interﬁber
matrix of BrM is largely composed of heparin sulfate and
chondroitin/dermatan sulfate, and it has been suggested that
the chondroitin sulfate side chains provide an electrolytic
barrier to diﬀusion. Maximum diﬀusion occurs at the
membrane isoelectric point of pH 5. At physiologic pH,
there is a negative charge, and this may impede the passage
of negatively charged macromolecules. Any alteration in
the structure or composition of BrM might inﬂuence its
diﬀusion properties and ultimately the function of the RPE
and outer retina [16–19].
3. What Is Age-Related Macular Degeneration
(AMD)?
AMD is typically classiﬁed into two clinical forms, “dry” or
“wet” (Figure 2), both of which can lead to visual loss. In the
dry or nonneovascular form, visual loss is usually gradual.
The hallmark changes that are seen in the macula are yellow
subretinal deposits called drusen, or RPE hyperpigmentary
or hypopigmentary irregularities. Drusen may enlarge
and become conﬂuent, and even evolve into drusenoid
RPE detachments, where the RPE becomes separated
from its underlying Bruch’s membrane. These drusenoid
detachments often progress to geographic atrophy, where
the RPE dies from apoptosis or into wet AMD. In the wet
form, also called exudative or neovascular AMD, vision
loss can occur suddenly when a choroidal neovascular
membrane develops in the sub-RPE, between the RPE andJournal of Lipids 3
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Figure 2: (a) Fundus photo of the right eye with early non-
neovascular (dry) AMD. Note the numerous yellow subretinal
deposits (Drusen). (b) Fundus photo of the right eye with advanced
nonneovascular AMD (Geographic atrophy). Note area where RPE
cells have died from apoptosis (arrowheads). (c) Fundus photo
of the right eye with neovascular or wet AMD. Note subretinal
hemorrhage (arrowheads) adjacent to a choroidal neovascular
membrane (arrows).
Bruch’s membrane, and it subretinal space, between the
neurosensoryretinaandRPE,anditleaksﬂuidorblood[16].
At present, the pathophysiology of AMD is incompletely
understood. AMD is a complex trait genetic disease modu-
lated by various nongenetic or “environmental” risk factors
[20]. Nonmodiﬁable risk factors include increasing age,
gender, and family history [20, 21]. To date, chronological
aging remains the strongest risk factor. A number of other
risk factors have also been reported to inﬂuence AMD,
including smoking, diet, higher body mass index, serum
cholesterol levels, cataract surgery, cardiovascular disease,
hypertension, and sunlight exposure [20–22]. Among these
factors, cigarette smoking is the strongest risk factor [23].
A “dose-response” eﬀect has been established since pack-
year smoking strongly correlates with AMD while smoking
cessation reduces the risk for AMD [24]. Epidemiologic data
from several large studies indicate that both AMD and dis-
easeprogressionarestronglyinﬂuencedbysmoking[22–26].
4. Histopathology of AMD
4.1. The RPE and Aging. The RPE is highly metabolically
active due to a number of specialized functions that sustain
photoreceptorhealth.Withadvancingage,RPEcellsundergo
an increase in pleomorphism, decrease in melanin content,
and an overall decrease in cell number within the posterior
pole [27]. For this study, we will focus our discussion on
photoreceptor processing because (a) photoreceptor outer
segments (POSs) are lipid rich and (b) of the magnitude of
POS processing by the RPE cell. Throughout life, RPE cells
utilize tremendous energy to phagocytose and recycle lipid-
rich POS back to the photoreceptors in order to preserve
visual function. In fact, the RPE cycles approximately 30,000
lipid-rich POS per day [28]. Disruption of this recycling
over time can result in RPE and photoreceptor dysfunction
in part, due to the accumulation of lipid and lipid per-
oxidation products [29]. Engulfed POSs are contained in
phagosomes which are processed in lysosomes and broken
down into their individual components for recycling. Aging
reduces the eﬃciency of lysosomal processing and results
in the accumulation of incompletely digested phospholipids
[30].
The accumulation of cellular lipid does not appear to
haveadeleteriousimpactuponRPEfunction.However,lipid
accumulation, combined with oxidative stress over time,
results in the formation of lipid peroxidation products, such
as 4-hydroxynonenal (HNE) and malondialdehyde (MDA)
[31]. Suzuki et al. found, within macular photoreceptors and
the RPE of normal eyes, increasing quantities of oxidized
phospholipids with advancing age [32]. Mechanistically,
these lipid peroxidation products prevent POS proteins from
lysosomal degradation [31]. The undigested end products
within the phagolysosome, or residual bodies, accumulate
with aging. Progressive accumulation of the undigested
lipid peroxidation products will stress the RPE, which can
ultimately induce apoptosis, a well-established process in
aging and AMD, unless they are removed from the cell
by exocytosis, transcytosis, or autophagy [33–37]. These4 Journal of Lipids
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Figure 3: Schematic image of the RPE-Bruch’s membrane-
choriocapillaris interface in AMD. Basal laminar deposits
(BlamDs; ∗∗) appear between the RPE cell and the RPE basement
membrane (RPE BM), while basal linear deposits (BlinDs; ∗)
localize at the inner collagenous layer (ICL) beneath the RPE
basement membrane. EL: elastin layer; OCL: outer collagenous
layer; arrowhead indicates endothelial cell basement membrane.
changescaninﬂuenceBruch’smembrane.Thereleasedparti-
clesincludingapoptoticparticlesintoBruch’smembranecan
become the inﬂammatory nidus for basal deposit and drusen
formation [13, 16, 38–43]. The impact of lipid peroxidation
product processing on the photoreceptors, RPE, and Bruch’s
membrane remains a relatively understudied area. Given the
potential impact on AMD, it appears to be a fruitful avenue
for future study.
4.2. Aging Bruch’s Membrane, Basal Deposits, and Drusen.
With chronological aging, Bruch’s membrane thickens and
develops heterogeneous deposits called basal deposits. The
location and composition of basal deposits help to distin-
guish aging from AMD changes. The earliest age-related
deposits are seen within the outer collagenous layer, and
occur as early as 19 years of age [44]. These outer layer
deposits are the main contributors to the generalized age-
related thickening of Bruch’s membrane. Deposits between
the RPE cell and its basement membrane, known as basal
laminar deposits or BlamD (Figure 3), are also an age-
related change when thin and homogeneous in composition.
Early lesions look identical to the RPE basement membrane
on electron microscopy and consist, in part, of normal
RPE basement membrane molecules such as collagen IV,
VI, laminin, and heparan sulfate proteoglycans, which
seem to result from either excess production or reduced
degradation[44–49]. Other proteins such as vitronectin,
MMP-7, TIMP-3, C3, and C5b-9 are found in both BlamD
and drusen [13, 50]. When BlamDs thicken and accumulate
heterogeneous debris, “long spacing collagen,” lipoproteins,
and inﬂammatory proteins, they are associated histopatho-
logically with AMD. When deposits accumulate within the
inner collagenous layer, they are designated as basal linear
deposits, or BlinDs (Figure 3), which is one of the strongest
histopathological markers for AMD. When suﬃcient debris,
including lipid, accumulates within BlinD to form a mound,
it can be seen clinically as large drusen (>125 μm) [49, 51,
52].
4.3. Histopathologic Evidence of Intraocular Lipid Particles
within Bruch’s Membrane. Lipid particles accumulate within
Bruch’s membrane in the exact location and prior to the
development of basal deposits or drusen. This observation
has led to the hypothesis that these lipid particles contribute
to drusen formation during the development of AMD.
Sarks et al. [53] ﬁrst described these lipid particles as
membranous debris within BrM, basal deposits, and drusen
within the macula. Membranous debris is visualized by
transmission electron microscopy (TEM) and appear as
irregularly shaped and sized particles (range 33 to 267nm
diameter) with empty interiors [51]. The varying size of
membranous debris may result from aggregations of parti-
cles, variable loading of lipids into lipoprotein particles, vari-
able degrees of extracellular lipoprotein hydrolysis, and/or
oxidative or enzymatic modiﬁcation of lipoproteins [54].
The presence of membranous debris seen on histopathologic
examination corresponds to large drusen and severe RPE
pigmentary changes in the central macula that are seen on
clinical examination [53, 55–58]. The Curcio lab has found
that much of the membranous debris is actually lipoprotein
particles [55].
On TEM, the lipid particles also appear as “electron
lucent” 75nm diameter round particles within BrM includ-
ing BlamD, BlinD, and drusen [59]. In the earliest BlinD
lesions, the electron lucent particles form a line within
the inner collagenous layer adjacent to the RPE basement
membrane [58–60]. Using lipid-sparing OTAP TEM, Curcio
et al. observed that these electron lucent particles are in
actuality, solid, 80 to 100nm diameter particles that occupy
>30% of the inner collagenous layer in normal eyes from
patients older than 60 years [59]. Using quick-freeze/deep-
etch electron microscopy, Ruberti et al. also identiﬁed lipid
particles that resemble lipoproteins, forming a thin, densely
packed layer external to the RPE basal lamina in old, normal
eyes, and theorized that these lipid particles may eventually
lead to a conﬂuent lipid wall capable of isolating the outer
retina from its choroidal blood supply [61]. The volume
fraction and mass occupied by these lipoprotein particles
were found to increase monotonically with age in both the
inner collagenous layer and elastic layer, but not in the
outer collagenous layer [62]. Importantly, the quantity of
lipoprotein-associated lipids found in BrM accounts for a
large portion of the accumulated lipids measured in this
tissue [62]. The pattern of lipoprotein particle accumulation
totheinnerportionofBruch’smembranehasbeentheorized
to originate potentially from the RPE rather than systemic
delivery via the choriocapillaris, as will be discussed below.
5. The LipidComposition of Aging Bruch’s
Membrane and Drusen
Recent work suggests that the lipoprotein particles within
Bruch’s membrane are distinct from plasma lipoproteins and
have been found to contain free and esteriﬁed cholesterol
[63], phosphatidylcholine (PC), and apolipoprotein B100Journal of Lipids 5
[64].Curcio etal.foundthatesteriﬁedcholesterolcomprised
60% of total cholesterol within these lipoproteins, and
esteriﬁed cholesterol was 7-fold higher in the macula than
periphery[59].TheesteriﬁedcholesterolwithinBrMwas16-
to 40-fold-enriched relative to plasma [59]. If the extracellu-
lardeposits oflipid were derived fromblood, more than90%
of phospholipid would be phosphatidylcholine. In actuality,
these lipoproteins are comprised of no more than 50%
phosphatidylcholine [59]. These compositional diﬀerences
suggest that these particles are distinct lipoproteins from
those in the plasma [59].
BrM lipoproteins are rich in the fatty acid linoleate
and poor in docosahexaenoate and contain unesteriﬁed
cholesterol at higher concentration than in the neurosensory
retina. Their density fraction contains apolipoproteins B100,
A-I, and E [64, 65]. As photoreceptor outer segments are rich
in docosohexanoate, the lack of this fatty acid in lipoproteins
suggests that there is an intermediary process within RPE
cells where fatty acids are repackaged for neutral lipid
secretion [57]. These ﬁndings indicate that the lipoproteins
in Bruch’s membrane cannot be derived directly from pho-
toreceptors without considerable intracellular processing by
the RPE, additional cholesterol sources, or both. Enzymatic
colorimetry, ﬂuorometry, electrospray ionization mass spec-
trometry (ESI/MS), and negative stain electron microscopy
showed that Bruch’s membrane lipoproteins are eluted in
two peaks. Peak 1 (plasma LDL-HDL density range) lipopro-
teins contain predominantly phospholipid and unesteriﬁed
cholesterol, which morphologically appeared heterogeneous.
Peak 2 (plasma VLDL density range) lipoproteins were
enriched with esteriﬁed cholesterol and were approximately
100 nm diameter round electron-lucent particles. Based on
these data, Li et al. concluded that BrM lipoproteins do not
resemble plasma lipoproteins in density proﬁle, cholesterol
distribution, or morphology [65].
Recent studies of drusen composition and substructure
have helped us to understand how these lesions form.
Drusen contains neutral lipids, with long chain fatty acid
cholesteryl esters and nonesteriﬁed cholesterol constituting
∼3.2% of the dry weight [60, 65, 66]a n dc a no c c u p yu p
to 37–44% of drusen volume [64]. Approximately, 30% of
drusen exhibit at their bases, 15-μm diameter cores that
are enriched in nonesteriﬁed cholesterol and nonﬁbrillar
amyloid [13]. Drusen also contains at least 29 diﬀerent
proteins, including apolipoproteins (e.g., apoE, apoB) [67,
68]. Other major proteins include vitronectin, complement
component 9, clusterin, and scavenger receptor B2 [35, 69].
These components suggest that the innate immune response
is involved in drusen formation.
6. Consequences of LipidAccumulation
in Bruch’s Membrane
While we know that some of the membranous debris that
Sarksetal.[53]ﬁrstcharacterizedislipoproteins,othershave
speculated that membranous debris is membrane-bound
packets of RPE cytoplasm released by the RPE [67], RPE
basal infoldings disintegrating with age [70], Muller cell
processes invading BlamD [55], or subcellular blebs after
sublethal cytotoxicity [71]. A 3-phase model of basal deposit
formation has been proposed which is based on progressive
RPE cell injury with early secretion of basement membrane
like material, polymerization or condensation of material
to produce long spacing collagen and dense amorphous
material, and ﬁnally, release of membranous debris that
comprises BlinD and large drusen [51].
In addition to the release of intracellular material, the
accumulation of lipoprotein particles in the inner collage-
nous layer with chronological aging, and their presence
within drusen, basal laminar, and linear deposits suggests
that their deposition is a critical antecedent event in the
formation of these histopathologic markers of AMD. AMD
lesion formation has thus been conceptualized as sharing
mechanisms with atherosclerotic plaque formation, where
LDL retention within the arterial wall initiates a cascade
of pathologic events called the “response to retention”
hypothesis [13]. In atherosclerosis, apolipoprotein B100
lipoproteins, due to a number of changes to the subendothe-
lial matrix, become trapped and then oxidatively modiﬁed.
These modiﬁcations stimulate diﬀerent biological processes
including innate immune system-mediated inﬂammation,
which induces a cascade of pathologic events that culminate
in atherosclerotic plaques [72]. In AMD, the following
evidence supports the “response to retention” hypothesis:
(1) apoB100-containing lipoproteins accumulate in BrM
in the same location as basal deposits and drusen, (2)
oxidatively modiﬁed proteins and lipids are present in BrM;
ourlaboratoryhasshownthatoxidizedapoB100lipoproteins
accumulate in BrM including drusen and basal deposits in
AMD and that oxidized lipoproteins induce a pathologic
phenotype to RPE cells [73], and (3) the accumulation of
inﬂammatory mediators within drusen and basal deposits
indicates a role for the innate immune response [50].
7. Consequence of OxidizedLipids
Oxidation of retained apoB100 lipoproteins is critical to the
development of atherosclerosis [72], and there is emerg-
ing evidence for oxidized lipoproteins in AMD. Oxidized
lipoproteins can trigger complement activation [74]. CD36
is the principal receptor implicated in uptake of oxidized
low-density lipoproteins and is expressed by the RPE. CD36
ligands also promote sterile inﬂammation through assembly
of a Toll-like receptor 4 and 6 heterodimer [75]. Uptake of
oxidized LDL by the RPE is CD36 dependent and appears
to bind to oxidized PAPC (1-palmitoyl-2-arachidonoyl-
sn-glycero-3-phosphocholine) and PLPC (1-palmitoyl-2-
linoleoyl-sn-glycero-3-phosphocholine) that are contained
in oxidized lipoproteins [76–78]. It appears therefore that
CD36 may have a role not only in the clearance of oxidized
lipids from BrM [79], but also in subsequently inducing an
immune response [75].
One pathogenic component of oxidized lipoproteins is
oxysterols, which are metabolites of unesteriﬁed cholesterol
that are generated in vivo either as a byproduct of mitochon-
drial enzymes or from LDL oxidation. In atherosclerosis,
oxysterols contribute to the conversion of macrophages into
foam cells [80] .T h eh u m a ne y ei sn o wk n o w nt op r o d u c e6 Journal of Lipids
signiﬁcant quantities of 7-ketocholesterol and related sub-
stances as a direct result of photoreceptor function. Much
of the oxysterols (7-ketocholesterol, 24-hydroxycholesterol,
25-hydroxycholesterol, 27-hydroxycholesterol) are gener-
ated from the oxidative conversion of cholesteryl esters.
Oxysterols have cytotoxic and proinﬂammatory properties
on RPE cells. For example, Dasari et al. have recently
shown that 27-hydroxycholesterol increases reactive oxygen
species generation, glutathione depletion, increased ER
stress, reduced mitochondrial membrane potential, Ca2+
dyshomeostasis, inﬂammation through activation of nuclear
factor κB( N F κB), Aβ peptide production, and eventually
apoptotic-mediated cell death in cultured RPE cells [81].
Oxysterols induce IL-8 production and secretion [82]. In
addition, RPE cells are able to uptake oxysterols at a high
rate. This raises the possibility that ingestion of suﬃcient
concentrations of oxysterols by RPE cells can induce an
inﬂammatory response or induce apoptosis. To date, while
no human histopathologic study has identiﬁed oxysterols
i nB r u c h ’ sm e m b r a n eo rd r u s e n ,7 - k e t o c h o l e s t e r o lh a s
recently been found to be localized in deposits within the
choriocapillaris and Bruch’s membrane of aging monkeys
[83]. Given the aging-associated accumulation of cholesteryl
esters in drusen and Bruch’s membrane as described above,
and their tendency to become oxidized into oxysterols, the
toxic role of 7-ketocholesterol and/or the failure to neutralize
oxysterolsmayexplaininparthowoxidizedlipoproteinsplay
a role in AMD and points towards a novel therapeutic target
[84].
8.The Originof Lipoproteins
Since lipoproteins are synthesized in the liver, the plasma
has been implicated as the source of lipoproteins which
accumulate in Bruch’s membrane [59, 85]. The apoB100
backbone and size of these particles suggest that they were
most closely related to LDL or VLDLs. This has prompted a
search for an association between serum lipid and AMD.
8.1. AMD and Systemic Lipid. To date, epidemiological
studies on the association between serum lipid and AMD
risk have been inconsistent [86–94]. Part of this variability
may have resulted from reporting diﬀerent forms and stages
of AMD with diﬀerent lipid proﬁles. For example, several
studies have not found an association between serum lipid
proﬁleandAMDrisk[86,88,91].ElevatedHDLbutnottotal
cholesterolwasassociatedwithanincreasedriskofAMDina
study by Van Leeuwen et al. [86]. Nonneovascular AMD was
unrelated to cholesterol level in a study by Hyman et al. [88].
No diﬀerence in total cholesterol, triglycerides, phospho-
lipids, high- and low-density lipoprotein-cholesterol (HDL-
C and LDL-C) concentrations were observed between AMD
patients and controls in the study by Abalain et al. [91], and
therewasnosigniﬁcantdiﬀerenceintheconcentrationofthe
Lipoprotein(a) between the AMD and control groups in the
work by Nowak et al. [92].
Some correlations between serum lipid and AMD have
been made when investigators have looked speciﬁcally at
high-density lipoproteins. Again, the results have been
conﬂicting. The Rotterdam [86] and Pathologies Oculaires
Liees al’Age [95] studies found an association between
AMD risk and high-density lipoprotein-cholesterol (HDL-
C). When separating by disease type, Klein et al. [87]
showed that higher serum HDL-C at baseline was associated
with pure geographic atrophy or advanced non-neovascular
AMD (RR per 10mg/dL HDL-C, 1.29; 95% CI, 1.05–1.58;
P = 0.01), while Hyman et al. [88] revealed a positive
associationbetweenHDLlevelandneovascular,butnotnon-
neovascular AMD (OR = 2.3), and dietary cholesterol level
(OR = 2.2).
On the other hand, diﬀerent studies have found an
inverse correlation with HDL and AMD risk. Reynolds
et al. [96] recently demonstrated that elevated HDL is
associated with a reduced risk of advanced AMD, especially
the neovascular (NV) subtype (P value < 0.05, 0.03, resp.),
and that higher low density lipoprotein (LDL) is associated
withincreasedriskofadvancedAMDandtheNVsubtype(P
value < 0.03, 0.04, resp.). When looking for an association of
serum lipids with advanced AMD in multivariate modeling,
Reynolds et al. also found signiﬁcant trends with a higher
quartile of LDL and increasing AMD risk (P for trend < 0.03,
0.01). Higher total cholesterol was also associated with AMD
risk when controlling for all covariates and genotypes.
These ﬁndings were compatible to ﬁndings in previous
largestudies,suchastheBlueMountainEyeStudy(BRMES),
a population based cohort study, and the Eye Disease Case
Control Study (EDCCS). The BRMES found that increased
HDL cholesterol was inversely related to incident late AMD
(RR per standard deviation (SD) increase, 0.74; 95% CI,
0.56–0.99). Elevated total/HDL cholesterol ratio predicted
late AMD (RR per SD increase, 1.35; 95% CI, 1.07–1.70) and
geographic atrophy (RR per SD, 1.63; 95% CI, 1.18–2.25)
[97]. The EDCCS also reported a statistically signiﬁcant 4-
fold increased risk of exudative AMD with the highest serum
cholesterol levels [93].
The association between the use of cholesterol-lowering
medications, including statins, and AMD has also been
intensively studied. Like the systemic lipid studies, these
results have also been inconsistent [98–105]. The Rotterdam
and several other studies did not ﬁnd a relationship between
cholesterol-lowering medication [98–100] including statins
[101] and risk of AMD. McGwin Jr. et al. [102] evaluated the
association between the use of cholesterol-lowering medica-
tions and AMD in the Atherosclerosis Risk in Communities
(ARIC) study, a large, prospective, population-based cohort
study conducted in four communities across the United
States. The large sample size in this study was a strength over
previous research on statins and AMD risk. Adjusting for the
confounding inﬂuence of age, gender, and race, the authors
found a signiﬁcant relationship between AMD and use of
cholesterol-lowering medications (OR, 0.79; 95% CI, 0.63–
0.99) [106].
8.2. AMD and Cardiovascular Diseases. Some studies have
suggested an association between AMD and clinical man-
ifestations of cardiovascular disease (CVD). For example,
results obtained from a cross-sectional, large population-
based study in The Netherlands showed a 4.5-fold increasedJournal of Lipids 7
risk of late AMD associated with atherosclerotic lesions at
the carotid bifurcation [16, 107]. Cardiovascular disease
and AMD share some of the same risk factors, including
high body mass index (BMI), elevated C-reactive protein
and other cytokines, and smoking history [16, 20, 21, 108–
110]. A study of 930 individuals found that serum C-
reactive protein was signiﬁcantly elevated in individuals with
advanced AMD [16, 111]. An epidemiologic correlation
between atherosclerosis and AMD has also been established
[94, 97]. It is possible that cardiovascular disease could
provide a comparison model for the role of cholesterol in
AMD pathogenesis [59]. The association of cardiovascular
disease with AMD, similar risk factors in both and evidence
oflipoproteindepositsinbothconditionsfavorstheresponse
to retention hypothesis in AMD.
8.3. Evidence for Local Production of Lipoproteins. BrM
lipoproteins do not resemble plasma lipoproteins in density
proﬁle, cholesterol distribution, and morphology. The tran-
scripts for apoB100, apoA-I, apoE, microsomal triglyceride
transfer protein, and other genes involved in lipoprotein
synthesis are expressed by the RPE [69, 112–114]. RPE
cell lines in vitro secrete lipoprotein particles [112, 115].
While the in vitro environment may not replicate the in
vivoconditions,theseobservationshaveraisedthepossibility
that the RPE assembles and secretes a large, possibly
novel, lipoprotein particle, and that the lipoproteins which
accumulate in Bruch’s membrane are locally rather than
systemically derived. Why would the RPE secrete lipopro-
teins? Cardiac myocytes are known to secrete lipoproteins
as a protective mechanism against the toxic accumulation
of lipid [116]. Large oil red O-binding intracellular droplets
have been reported in the RPE with aging which could
stimulate the synthesis and secretion of lipoproteins [115].
An obvious potential source, not present in other cell types
for lipid accumulation, is the constant recycling of POS
tips by the RPE. In fact, as mentioned above, the RPE
cycles approximately 30,000 lipid rich POS tips per day [28].
The excess lipid, such as phospholipids and unesteriﬁed
cholesterol derived from POS, after being internalized within
the RPE could therefore serve as a source for lipoprotein
formation. The apparent dissimilarity in lipid composition
between BrM lipoproteins and POS tips can be reconciled
by a complex intracellular lipid processing by the RPE where
certain elements, such as docosahexaenoate are recycled
to the POS, and other lipids are instead packaged into
lipoproteins for secretion in the Bruch’s membrane for
systemic elimination via the choriocapillaris [117]. The
RPE contains lipoprotein receptors and thus internalize
lipoproteins [118–120]. Curcio et al. have postulated that the
BrM lipoprotein is a consequence of the RPE eliminating
remnants of lipoprotein components after the RPE has
extracted speciﬁc nutrients (e.g., xanthophylls, cholesterol,
and vitamin E) for use by photoreceptors. According to
this model, cholesteryl ester-rich lipoproteins from plasma
are taken up by RPE, stripped of nutrients, and repackaged
for secretion in BrM as large, cholesteryl ester-rich apoB-
lipoproteins [13].
This theory does not eliminate the possibility that
lipoproteins that accumulate in Bruch’s membrane are of
hepatic or intestinal origin arriving from the plasma, espe-
cially because lipoproteins are delivered to the retina for
nutrition. The evidence against systemic delivery of lipopro-
teins in Bruch’s membrane at this time is based primarily
on the distinct diﬀerences in size and lipid composition.
The variable size, however, could be the result of lipoprotein
aggregationorenzymaticprocessing.Likewise,thediﬀerence
in lipid composition could be the result of local enzymatic
processing after lipoproteins become retained in Bruch’s
membrane. Identiﬁcation of the relative contribution by
the RPE and the systemic circulation would be helpful in
devising treatments that target reducing lipoprotein accu-
mulation to reduce drusen formation.
9. AMD and Lipid-RelatedGenes
Recently, genetic information has provided novel insights
into the development of AMD. The most replicated linkage
signals have been identiﬁed at 1q25-31 and 10q26 [16,
121]. These studies have also identiﬁed polymorphisms in
complement factor H, C3, HTRA1, ARMS2, and mito-
chondrial DNA polymorphism A4917G as risk factors,
and complement factor B and apolipoprotein E4 (APOE4)
as protective factors [122–128]. Just as the discovery of
complement factor H has provided an unexpected role for
complement-mediated inﬂammation in the development of
AMD[125,129–131],recentlyidentiﬁedgeneticlinksoflipid
related genes may provide further insights into how lipid
biology inﬂuences AMD.
Several genome-wide scans have been published recently,
inwhichseverallipid-relatedgeneshavebeenassociatedwith
AMD risk. The gene of apolipoprotein E (ApoE) encodes
for a plasma protein participating in the metabolism of
cholesterol and other lipids [132], and since it is found in
drusen [133, 134], it has been evaluated genetically for an
association with AMD risk. Apo E2 (Cys 112, Cys 158), Apo
E3 (Cys 112, Arg 158), and Apo E4 (Arg 112, Arg 158) are
encoded by three alleles: epsilon 2, epsilon 3, and epsilon
4, respectively, which are located on chromosome19 [132].
These three main isoforms are known to diﬀer in one amino
acid at one of the two primary protein sites, which alters
their function. While some studies show little association of
apoE and AMD risk [135], other well-conducted studies do
provide evidence for an association with AMD. Most studies
conﬁrm that the ApoE ε4 allele is a protective variant of the
gene that diminishes the risk for developing AMD [136]a n d
i t sl a t ef o r m[ 127] and also reduces the risk of developing
AMDinindividualswithafamilyhistory[137].Subjectswho
hadatleastoneepsilon4allelehadahighermacularpigment
optical density across the macula than subjects without this
allele, which may provide protection against photo-oxidative
damage [138]. Meanwhile the ε2 allele, on the contrary, has
been linked with the risk of developing AMD [127, 139].
The frequencies of the E2 and E4 alleles in Caucasians
are approximately 8% and 15%, respectively. Allele- and
genotype-based tests of association have indicated a risk
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to 40% for E4. E2 appears to act in a recessive mode and E4
in a dominant model [136]. Souied et al. have oﬀered two
diﬀerent hypotheses explaining the protective mechanism of
Apo E4 in the development of AMD. Apo E4, in contrast
to Apo E2 and 3, does not contain disulﬁde bridges;
therefore, being smaller, it may be more eﬀectively trans-
ported through Bruch’s membrane. Alternatively, apo E4 is
positively charged while E2 and E3 are negatively charged.
This diﬀerence in charge may contribute to diﬀerences in
their abilityto cleardebris throughBruch’s membrane[127].
Ironically, the Apo E4 allele is associated with hyper-
cholesterolemia and greater risk of ischemic heart disease,
whereas the Apo E2 allele is considered a protective factor
against the development of this disorder [127]. The ApoE ε4
allele is associated with increased risk and earlier onset of
Alzheimer disease (AD), and conversely the ApoE2 allele is
protective against AD [139].
The eﬀect of ApoE on AMD risk is not consistent with
ﬁndings in AD and ischemic heart disease. However, the
capacity of Apo E to mediate cholesterol eﬄux from cells
suggests that its function as a cholesterol carrier protein may
be involved in AMD. Variability in the eﬃcacy of cholesterol
redistribution may account for the association of Apo E with
AMD. Moreover, Apo E is an Aβ-binding protein and may
thereby be involved in Aβ aggregation and clearance, which
may account for the speciﬁc association with AMD. Finally,
C-terminal truncated toxic fragments of ApoE can enter the
cytosol and exert detrimental eﬀects on the cytoskeleton and
mitochondria which may lead to cell death [140].
Curcio el al. [13] suggested the following scenario as a
possible way in which apoE might have diﬀerent eﬀects in
AMD and CVD. In atherosclerosis, cholesterol eﬄux into
the intima prevents macrophages from diﬀerentiating into
foam cells, and apoE4 hinders this eﬄux, thus exacerbating
atherosclerosis. In AMD, cholesterol exported from the RPE
within lipoproteins accumulatesin BrM and promotes lesion
formation. Perhaps the opposing eﬀect of cellular cholesterol
export into BrM and the vascular intima helps to explain the
opposite direction of apoE4’s inﬂuence in AMD and CAD.
This theory presumes that a signiﬁcant source of Bruch’s
membrane lipid originates from the RPE.
Hepatic lipase (LIPC), a gene located on chromosome
15q22, was recently discovered to be associated with AMD in
a large, genome-wide association study by Neale et al. [141].
LIPC encodes hepatic triglyceride lipase, which catalyzes the
hydrolysis of phospholipids, monoglycerides, diglycerides,
triglycerides,andacyl-CoAthioestersandisacriticalenzyme
in HDL metabolism. Hepatic lipase also binds heparin
and has the dual functions of a triglyceride hydrolase and
a ligand/bridging factor for receptor-mediated lipoprotein
uptake. This genetic ﬁnding has been replicated in another
genome-wide association study by Chen et al. [142], who
showed strong association signals with alleles at two loci
(LIPC, P = 1.3 × 10
−7;C E T P ,P = 7.4 × 10
−7) that
were previously associated with high-density lipoprotein
cholesterol (HDL-C) levels in blood. They also observed an
association with AMD and HDL-C-associated alleles near
lipoprotein lipase (LPL; P = 3.0 × 10
−3) and ATP-binding
cassette (ABCA1; P = 5.6 ×10
−4)[ 142].
Reynolds et al. [96] explored the relationship between
the LIPC genotype and serum lipids. The mean HDL level
increased with each T allele of the LIPC gene (P<0.05
for trend). Total cholesterol, LDL, and triglycerides were not
signiﬁcantlyassociatedwithLIPC.Modelscontrollingforage
and other covariates not including HDL showed a protective
eﬀect of LIPC on AMD. Their results showed that the TT
genotype of the LIPC gene was associated with a reduced
risk of both neovascular and geographic atrophy subtypes
of advanced AMD [96]. There was a trend for increasing
HDL with increasing LIPC T alleles. However, HDL level
did not seem to mediate the association between LIPC and
AMD based on the independent associations of both LIPC
and HDL when considered simultaneously [96]. Thus, at
present, while a genetic link for LIPC and AMD has been
established, the present epidemiologic evidence suggests that
LIPC’s eﬀect is not mediated through plasma HDLs. In fact,
Neale et al. postulated that the LIPC association may not be
the result of an eﬀect on HDL levels, but it could represent a
pleiotropic eﬀect of the same functional component [141].
Since LIPC is expressed in the retina, an undeﬁned local
eﬀect by LIPC that protects against AMD is possible [141].
Future studies determining the role of LIPC in the eye may
provide insight into its contribution to AMD pathology.
Several other genes that have a role in lipid metabolism
have been reported to have an association with AMD. For
example, the ABC transporters play pivotal roles in cellular
lipid transport, and mutations in ABCA-transporter genes
have been shown to result in hereditary diseases involving
major physiological processes in the cardiovascular, res-
piratory, visual, and integumentary systems. Accumulated
evidence also suggests that ABCA-transporters play critical
roles in the pathogenesis of complex multifactorial disorders
with a high incidence such as atherosclerosis, AMD, and
Alzheimer’s disease [143]. Expression of reverse cholesterol
transport proteins ATP-binding cassette A1 (ABCA1) and
scavenger receptor BI (SR-BI) in the retina and retinal
pigmented epithelium has been reported. RPE cells may
utilize reverse cholesterol transport (RCT) activity to move
lipid into BrM, mediated through ABCA1 and SR-BI [144].
ApolymorphisminElongationofverylongchainfattyacids-
like 4 (ELOVL4), which is involved in fatty acid biosynthesis,
is also associated with AMD [145], but the role of this gene
in AMD has not been conﬁrmed in other studies [146].
In a study conducted in French and north American
AMD patients and control group who did not carry the
prevalent complement factor H (CFH) nor age-related
maculopathy susceptibility 2 (ARMS2) polymorphisms, an
association between AMD and the scavenger receptor class
B member 1 (SCARB1) gene was seen among the study
subjects. SNP rs5888 of the SCARB1 gene codes for SRBI,
which is involved in the lipid and lutein pathways. The
genotypic distribution of the rs5888 polymorphism was
signiﬁcantly diﬀerent between cases and controls in the
French population (P<0.006). Heterozygosity at the rs5888
SNP increased risk of AMD compared to the CC genotypes
[147]. SRB1, a multiligand cell surface receptor, is known toJournal of Lipids 9
mediate selective cholesterol uptake and cholesterol eﬄux.
Furthermore, recent studies have shown that SCARB1 is also
involved in uptake of vitamin E and lutein giving further
support to a possible role of SCARB1 in AMD.
10. Conclusions
Atpresent,theaboveepidemiologic,molecular,andcellbiol-
ogy, and genetic studies have not integrated the ﬁndings into
a uniﬁed explanation for the role of lipids and lipoproteins
in AMD. To establish a uniﬁed role for lipids in AMD,
future studies should utilize the following evidence in their
design, as outlined in this paper: (1) lipoproteins, which
have a composition that is distinct from plasma lipoproteins,
accumulateinBruch’smembranewithagingbeforehallmark
Bruch’s membrane AMD lesions. (2) Oxidized lipoproteins
have been identiﬁed in Bruch’s membrane, basal deposits,
and drusen of AMD specimens, suggesting a possible trigger
for the induction of inﬂammation and drusen formation.
(3) Multiple epidemiologic studies suggest no substantive
role of plasma lipoproteins in AMD, and therefore reduce
the likelihood of plasma lipoproteins as a source of Bruch’s
membrane lipoprotein accumulation. (4) Cell biology and
molecular pathology studies suggest a role for local that is
RPE synthesis and secretion of apoB100 lipoproteins as a
plausible explanation for their origin in Bruch’s membrane.
The deﬁnitive study that would determine the origin of
Bruch’s membrane lipoproteins would be to topographically
knock out lipoprotein production in the liver, the eye,
both, and neither, to determine the relative contribution
of lipoprotein accumulation in Bruch’s membrane under
these experimental conditions. Given the availability of
genetically altered mice related to lipoprotein metabolism
and Cre recombinase technology to topographically knock
out a gene of interest, this experiment is feasible and is,
in fact, ongoing in our laboratory. (5) Genetic variations
have been identiﬁed as increasing risk for AMD. Establishing
mechanisticevidenceoftheselipid-relatedgeneswithaspects
ofanAMDphenotypeinanimalmodelswilldeﬁnetheirbio-
logic contribution. Alternatively, the epidemiologists could,
in future studies, analyze the role of plasma lipids in the
context of genotype before eliminating the role of systemic
lipids in AMD. This approach may not identify systemic
lipids as a major risk factor in AMD, but it might identify
susceptibility in a subset of patients who are at risk for
AMD because of genotype and plasma lipid levels. While
lipoproteins in Bruch’s membrane both accumulate and can
become oxidized, experimental proof of establishing how
lipoprotein accumulation in Bruch’s membrane leads to RPE
cell death or drusen formation is currently lacking and
would establish a deﬁnitive role for lipids in AMD. In the
future, it will be necessary for the epidemiologists, genetics,
and molecular and cellular biologists to work together
to deﬁnitively determine how lipid biology inﬂuences the
development of AMD. It is hoped that greater understanding
of the molecular biology of AMD lesions will provide a
knowledge based on which to develop multiple treatment
targets for the beneﬁt of patients with AMD.
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